Tarsus Pharmaceuticals, Inc (TARS) insider trading

Every open-market stock purchase and sale by Tarsus Pharmaceuticals, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Elizabeth Yeu Lin (C-suite exec) and 3 others sold $5.1M in the last 90 days.
  • Last insider buy: Andrew D. Goldberg (Director), $19K, 2 years ago.

Last 12 months: insiders bought $0 (0 buys) and sold $19.8M (25 sales). Last close $70.50 on Oct 21, 2026.

Recent TARS insider trades

DateInsiderTradeValue
Sep 15, 2026William J Link Phd (Director)Sold$915K
Sep 15, 2026William J Link Phd (Director)Sold$60K
Sep 15, 2026William J Link Phd (Director)Sold$5.3K
Sep 15, 2026Wendy L Yarno (Director)Bought (not open market)—
Sep 15, 2026David E I Pyott (Director)Bought (not open market)—
Sep 15, 2026William J Link Phd (Director)Bought (not open market)—
Sep 4, 2026Bobak R. Azamian (CEO)Sold$641K
Sep 4, 2026Elizabeth Yeu Lin (C-suite exec)Sold$485K
Sep 4, 2026Elizabeth Yeu Lin (C-suite exec)Sold$458K
Sep 4, 2026Seshadri Neervannan (COO)Sold$388K
Sep 4, 2026Bobak R. Azamian (CEO)Sold$265K
Sep 4, 2026Elizabeth Yeu Lin (C-suite exec)Sold$143K
Sep 2, 2026Bobak R. Azamian (CEO)Sold$801K
Sep 2, 2026Elizabeth Yeu Lin (C-suite exec)Sold$431K
Sep 2, 2026Elizabeth Yeu Lin (C-suite exec)Sold$127K
Sep 1, 2026Elizabeth Yeu Lin (C-suite exec)Sold$340K
Jun 25, 2026Bhaskar Chaudhuri (Director)Bought (not open market)—
Jun 25, 2026William J Link Phd (Director)Bought (not open market)—
Jun 25, 2026Wendy L Yarno (Director)Bought (not open market)—
Jun 25, 2026Wendy L Yarno (Director)Bought (not open market)—
Jun 25, 2026Wendy L Yarno (Director)Bought (not open market)—
Jun 25, 2026Bhaskar Chaudhuri (Director)Bought (not open market)—
Jun 25, 2026David E I Pyott (Director)Bought (not open market)—
Jun 25, 2026David E I Pyott (Director)Bought (not open market)—
Jun 25, 2026David E I Pyott (Director)Bought (not open market)—

Who's trading TARS

Get free alerts when an insider at Tarsus Pharmaceuticals, Inc files a new trade →